Generic Pharmasec reports standalone net loss of Rs 0.61 crore in the September 2021 quarter

Jamnagar/Surat (Gujarat) [India], July 29 (ANI/PNN): In line with the Company’s strategy to extend Point of Care Diagnostic footprint by focusing on Channel and Dealers network and thereby enhancing its sales turnover, BSE listed M/s Generic

Generic Pharmasec Ltd. successfully executes an order from Reliance Group

The Company is in dialogue with Reliance Group for further orders and implementation for their Group hospitals at various other locations.

Generic Pharmasec successfully executes order from Reliance Group

Generic Pharmasec standalone net profit rises 445.65% in the March 2021 quarter

The agreement has just now become effective and covers the entire length & breadth of the country.

Generic Pharmasec enters into agreement with Abbott Point of Care (APOC)

Generic Pharmasec standalone net profit declines 80.00% in the December 2020 quarter

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Average profitability - not good, not bad

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Generic Pharmasec Ltd is an India-based company. The Company is focused on trading and dealing in chemicals.